{
  "id": 260,
  "text": "While the 2014 Bethesda System recommended the concurrent use of LSIL and atypical squamous cells, cannot exclude HSIL (ASC-H) in the diagnosis for these cases, alternative reporting options (such as adopting the intermediate category of LSIL, cannot exclude HSIL, or LSILH) have been advocated by some authors (30, 31).",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: While the 2014 Bethesda System recommended the concurrent use of LSIL and atypical squamous cells, cannot exclude HSIL (ASC-H) in the diagnosis for these cases, alternative reporting options (such as adopting the intermediate category of LSIL, cannot exclude HSIL, or LSILH) have been advocated by some authors (30, 31).\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "在宫颈液基细胞学检查中，当同时出现低度鳞状上皮内病变（LSIL）和非典型鳞状上皮细胞但不能排除高度鳞状上皮内病变（ASC-H）时，根据2014年Bethesda系统的建议，可以同时报告为LSIL和ASC-H。对于一些作者提出的替代报告方式，可以考虑使用“LSIL，不能排除HSIL（LSIL-H）”作为中间分类，以更好地表达病变性质和临床意义。这种分类旨在提供更明确的诊断指引，帮助临床医生采取适当的后续管理措施，例如进一步的阴道镜检查或组织学评估。",
  "query": "**在宫颈液基细胞学检查中，当低度鳞状上皮内病变（LSIL）和非典型鳞状上皮细胞但不能排除高度鳞状上皮内病变（ASC-H）同时出现时，有哪些诊断或报告分类的建议？**",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: **在宫颈液基细胞学检查中，当低度鳞状上皮内病变（LSIL）和非典型鳞状上皮细胞但不能排除高度鳞状上皮内病变（ASC-H）同时出现时，有哪些诊断或报告分类的建议？**\n\n<reference text>: While the 2014 Bethesda System recommended the concurrent use of LSIL and atypical squamous cells, cannot exclude HSIL (ASC-H) in the diagnosis for these cases, alternative reporting options (such as adopting the intermediate category of LSIL, cannot exclude HSIL, or LSILH) have been advocated by some authors (30, 31).\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "在宫颈液基细胞学检查中，当同时出现低度鳞状上皮内病变（LSIL）和非典型鳞状上皮细胞但不能排除高度鳞状上皮内病变（ASC-H）时，根据2014年Bethesda系统的建议，可以同时报告为LSIL和ASC-H。对于一些作者提出的替代报告方式，可以考虑使用“LSIL，不能排除HSIL（LSIL-H）”作为中间分类，以更好地表达病变性质和临床意义。这种分类旨在提供更明确的诊断指引，帮助临床医生采取适当的后续管理措施，例如进一步的阴道镜检查或组织学评估。"
}